Antibody titres decline 3-month post-vaccination with BNT162b2

  title={Antibody titres decline 3-month post-vaccination with BNT162b2},
  author={Julien Favresse and Jean-Louis Bayart and François Mullier and Marc Elsen and Christine Eucher and Sandrine van Eeckhoudt and Tatiana Roy and Gr{\'e}goire Wieers and Christine Laurent and Jean Michel Dogn{\'e} and M{\'e}lanie Closset and Jonathan Douxfils},
  journal={Emerging Microbes \& Infections},
  pages={1495 - 1498}
ABSTRACT Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID… 

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Whether this decrease in antibody levels correlates with an equivalent drop in the clinical effectiveness against the virus would require appropriate clinical studies.

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

Overall this study clearly shows antibody persistence at 6 months, albeit with a certain decline, and the use of this vaccine in addressing the COVID-19 pandemic is supported by the results that in turn open debate about the need for further boosts.

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine

Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination, suggesting post- vaccination infection is possible even in the presence of a high anti-S serum antibodies titer.

Profound decline of antibody titers 6 months after BNT162b2 vaccination in healthy volunteers

Antibody titers were evaluated using a newly established, highly sensitive, fully automated chemiluminescent enzyme immunoassay (CLEIA) designed to specifically detect IgG or IgM against the SARS-CoV-2 spike protein receptor-binding domain (RBD).

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study

It is found that after two doses of vaccine there is a strong humoral response, but the immunity lowers six months later, while for those who have been in contact with the virus, they all had an antibody titer well above the laboratory limit.

Immune response (IgG) following full inoculation with BNT162b2 COVID-19 mRNA among healthcare professionals

It is demonstrated that the immune response after receiving the BNT162b2 COVID-19 mRNA vaccine is dependent on various modifiable and non-modifiable factors and the need for prospective immunosurveillance studies in order to estimate the duration of immunity.

Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study

Seven months after vaccination, the median IgGS titer had decreased by more than 92% both in individuals previously infected with SARS-CoV-2 and in uninfected individuals, but IgGS antibodies were still detected in all study participants and persisted throughout the 7 months after the second dose of the vaccine.

Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection

The study demonstrated that persons with a history of SARS-CoV-2 infection had significantly higher antibody levels (taking into account gender, age, type of work performed, and severity of post-vaccination symptoms) than employees without a History of COVID-19.



Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.

Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study

Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection

Serological assays showed a clinically significant difference to detect past SARS-CoV-2 infection with total antibody assays presenting the highest positivity rates and the waning effect reported in several studies should be interpreted with caution.

Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination

A significant difference exists in post-mRNA COVID-19 vaccine immune response in baseline seronegative and seropositive subjects, which seems dependent on age and sex in ser onegative subjects, as well as on baseline anti-SARS-CoV-2 antibodies level in seropOSitive patients.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals, and assessing virus-specific immune memory over at least a 6-month period is likely necessary to ascertain the durability of immune memory to SARS-CoV-2.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection is provided that will assist in developing vaccine strategies to control the future trajectory of the pandemic.

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

This work describes mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adult and describes the durability of protection against coronavirus disease 2019.